PTC Therapeutics (PTCT) Scheduled to Post Earnings on Tuesday

PTC Therapeutics (NASDAQ:PTCTGet Rating) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 3rd. Analysts expect PTC Therapeutics to post earnings of ($1.70) per share for the quarter. PTC Therapeutics has set its FY 2022 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

PTC Therapeutics (NASDAQ:PTCTGet Rating) last announced its quarterly earnings data on Tuesday, February 22nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.24). PTC Therapeutics had a negative net margin of 97.27% and a negative return on equity of 351.90%. The company had revenue of $165.20 million for the quarter, compared to the consensus estimate of $161.08 million. During the same quarter in the previous year, the business earned ($1.08) EPS. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, analysts expect PTC Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of PTCT opened at $40.15 on Tuesday. PTC Therapeutics has a 1-year low of $32.44 and a 1-year high of $47.20. The company has a 50-day moving average of $38.53 and a 200 day moving average of $39.07. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -5.40 and a beta of 0.89. The company has a debt-to-equity ratio of 679.17, a current ratio of 1.87 and a quick ratio of 1.84.

A number of equities research analysts recently weighed in on the stock. Barclays decreased their price objective on shares of PTC Therapeutics from $40.00 to $39.00 and set an “equal weight” rating for the company in a report on Wednesday, February 23rd. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “sell” rating in a report on Wednesday, January 26th. Cantor Fitzgerald restated an “overweight” rating and issued a $63.00 price target (down previously from $64.00) on shares of PTC Therapeutics in a report on Friday, April 1st. JPMorgan Chase & Co. boosted their price target on shares of PTC Therapeutics from $70.00 to $76.00 and gave the company an “overweight” rating in a report on Wednesday, February 23rd. Finally, StockNews.com assumed coverage on shares of PTC Therapeutics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $51.70.

In related news, VP Mark Elliott Boulding sold 779 shares of the business’s stock in a transaction that occurred on Tuesday, February 1st. The shares were sold at an average price of $40.00, for a total transaction of $31,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stuart Walter Peltz sold 1,961 shares of the business’s stock in a transaction that occurred on Tuesday, February 1st. The stock was sold at an average price of $40.00, for a total transaction of $78,440.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,900 shares of company stock valued at $1,445,210. 5.00% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in PTCT. Jane Street Group LLC grew its position in PTC Therapeutics by 299.2% during the 3rd quarter. Jane Street Group LLC now owns 11,576 shares of the biopharmaceutical company’s stock worth $431,000 after purchasing an additional 8,676 shares during the last quarter. Millennium Management LLC grew its position in PTC Therapeutics by 118.1% during the 3rd quarter. Millennium Management LLC now owns 12,436 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 6,735 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in PTC Therapeutics by 383.1% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 12,517 shares of the biopharmaceutical company’s stock worth $466,000 after purchasing an additional 9,926 shares during the last quarter. UBS Group AG grew its position in PTC Therapeutics by 67,450.5% during the 3rd quarter. UBS Group AG now owns 62,822 shares of the biopharmaceutical company’s stock worth $2,338,000 after purchasing an additional 62,729 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of PTC Therapeutics by 5.2% in the 4th quarter. Wells Fargo & Company MN now owns 60,605 shares of the biopharmaceutical company’s stock valued at $2,413,000 after acquiring an additional 2,994 shares during the last quarter.

About PTC Therapeutics (Get Rating)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.

See Also

Earnings History for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.